Marcos Langtry

Marcos Langtry is Head of Allogeneic Cell Therapy at Lonza Pharma & Biotech. He is responsible for the allogeneic commercial strategy, current and future offerings and portfolio optimization. Before joining Lonza, Marcos Langtry held several senior level positions with TiGenix, AstraZeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he acquired extensive experience with aseptically filled, biologic and cell therapy products.
Marcos Langtry holds a Master’s degree in Biochemical Engineering from University College London (UK) and an MBA from Imperial College London (UK), and is qualified as Chartered Engineer (CEng) and Chartered Scientist (CSci).